In the setting of hypopharyngeal carcinoma, administration of acRoots repressed tumor growth through decreasing E2F1 expression and inhibiting lncRNA MNX1-AS1 activity (Zheng et al., 2022), which holds immense potential for medical interventions treating E2F1 dysregulated cancers, although more holistic evidence should be presented in the clinical settings. The gene discussed is E2F1; the disease is cancer.